OBJECTIVES: Levels of soluble receptor for advanced glycation endproducts (sRAGE) have been linked to several components of the metabolic syndrome. We tested the hypothesis that plasma levels of sRAGE may be associated with non-alcoholic fatty liver disease. DESIGN AND METHODS: We enrolled subjects with definite nonalcoholic steatohepatitis (NASH, n=40), borderline NASH (n=8), simple fatty liver (n=9) and healthy controls (n=14). Plasma levels of sRAGE were measured by ELISA. RESULTS: Concentrations of sRAGE were significantly lower in patients with definite NASH (1080+/-392 pg/mL, P<0.01) and borderline NASH (1050+/-278 pg/mL, P<0.05) compared to controls (1480+/-387 pg/mL). Levels of sRAGE were significantly and inversely correlated with ALT (r=-0.30, P<0.05) and AST (r=-0.23, P<0.05). CONCLUSION: Plasma levels of sRAGE are significantly reduced in definite and borderline NASH.
OBJECTIVES: Levels of soluble receptor for advanced glycation endproducts (sRAGE) have been linked to several components of the metabolic syndrome. We tested the hypothesis that plasma levels of sRAGE may be associated with non-alcoholic fatty liver disease. DESIGN AND METHODS: We enrolled subjects with definite nonalcoholic steatohepatitis (NASH, n=40), borderline NASH (n=8), simple fatty liver (n=9) and healthy controls (n=14). Plasma levels of sRAGE were measured by ELISA. RESULTS: Concentrations of sRAGE were significantly lower in patients with definite NASH (1080+/-392 pg/mL, P<0.01) and borderline NASH (1050+/-278 pg/mL, P<0.05) compared to controls (1480+/-387 pg/mL). Levels of sRAGE were significantly and inversely correlated with ALT (r=-0.30, P<0.05) and AST (r=-0.23, P<0.05). CONCLUSION: Plasma levels of sRAGE are significantly reduced in definite and borderline NASH.
Authors: Barry I Hudson; Yeseon Park Moon; Anastasia Z Kalea; Minesh Khatri; Chensy Marquez; Ann Marie Schmidt; Myunghee C Paik; Mitsuhiro Yoshita; Ralph L Sacco; Charles DeCarli; Clinton B Wright; Mitchell S V Elkind Journal: Atherosclerosis Date: 2011-01-21 Impact factor: 5.162
Authors: Sofie M A Walenbergh; Tom Houben; Sander S Rensen; Veerle Bieghs; Tim Hendrikx; Patrick J van Gorp; Yvonne Oligschlaeger; Mike L J Jeurissen; Marion J J Gijbels; Wim A Buurman; Anita C E Vreugdenhil; Jan Willem M Greve; Jogchum Plat; Marten H Hofker; Satish Kalhan; Jussi Pihlajamäki; Patrick Lindsey; Ger H Koek; Ronit Shiri-Sverdlov Journal: Sci Rep Date: 2016-12-06 Impact factor: 4.379
Authors: Juliana Célia de F Santos; Iara B Valentim; Orlando R P de Araújo; Terezinha da R Ataide; Marília O F Goulart Journal: Int J Mol Sci Date: 2013-10-01 Impact factor: 5.923
Authors: Christos Spanos; Elaina M Maldonado; Ciarán P Fisher; Petchpailin Leenutaphong; Ernesto Oviedo-Orta; David Windridge; Francisco J Salguero; Alexandra Bermúdez-Fajardo; Mark E Weeks; Caroline Evans; Bernard M Corfe; Naila Rabbani; Paul J Thornalley; Michael H Miller; Huan Wang; John F Dillon; Alberto Quaglia; Anil Dhawan; Emer Fitzpatrick; J Bernadette Moore Journal: Proteome Sci Date: 2018-02-14 Impact factor: 2.480